Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The trial also demonstrated significant improvements across multiple secondary endpoints
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Huwel’s diagnostic solutions leverage open RT-PCR system
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Subscribe To Our Newsletter & Stay Updated
